Adverse drug reactions cause millions of hospitalisations annually, yet remain underreported in India. When it comes to the ...

Savara faces an FDA setback for Molbreevi, its aPAP treatment. Learn how the company plans to recover and file a new BLA by ...

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychother ...

Tea and coffee contain caffeine, antioxidants, and other beneficial nutrients. Both beverages offer potential health benefits ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.

FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...